Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||LY2090314 + Talazoparib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LY2090314||LY-2090314|LY 2090314||GSK3 Inhibitor (Pan) 3||LY2090314 inhibits glycogen synthase kinase 3 (GSK3), therefore activates Wnt signaling pathway and leads to apoptosis in tumor cells (PMID: 25915038, PMID: 26735141, PMID: 32391602).|
|Talazoparib||Talzenna||BMN673||PARP Inhibitor (Pan) 22||Talzenna (talazoparib) is an inhibitor of PARP1 and PARP2, which prevents the DNA repair of single strand DNA breaks, thus causing the accumulation of DNA strand breaks, genomic instability and apoptosis, and leads to lethality in homologous recombination repair deficient cells (PMID: 28242752). Talzenna (talazoparib) is FDA approved for use in patients with ERBB2 (HER2)-negative breast cancer harboring deleterious or suspected deleterious germline BRCA mutations (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||colorectal cancer||not applicable||LY2090314 + Talazoparib||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with LY2090314 sensitized colorectal cancer cell lines with either BRCA1/2 proficiency or BRCA2 deficiency to Talzenna (talazoparib) in culture, resulting in a synergistic effect (PMID: 33589588).||33589588|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|